SCHEMBL259371

SCHEMBL259371

Cc1cccc(NC(=O)c2ccnc(Cl)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.66
MEN1 O00255 4/20 0.66
RXFP1 Q9HBX9 1/20 0.66
KCNK3 O14649 8/20 0.63
KCNK9 Q9NPC2 7/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
ALDH1A1 P00352 1/20 0.63
LMNA P02545 1/20 0.63
KCNH2 Q12809 1/20 0.61
POLB P06746 1/20 0.57
NT5E P21589 1/20 0.56
RAB9A P51151 3/20 0.54
HTT P42858 1/20 0.54
NPC1 O15118 2/20 0.53
TP53 P04637 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
CSF1R P07333 1/20 0.53
BRAF P15056 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736261 0.84 LMNA (0.62) KCNK3KCNK9SMN1; SMN2ALDH1A1LMNA
SCHEMBL14308003 0.83 MEN1 (0.66) KMT2AMEN1RXFP1KCNK3KCNK9
SCHEMBL15238366 0.83 KCNK3 (0.67) KMT2AMEN1RXFP1KCNK3KCNK9
SCHEMBL1517075 0.83 BRAF (0.53) KMT2AMEN1KCNK3KCNK9SMN1; SMN2
SCHEMBL16430829 0.83 PTGS1 (0.54) KCNK3KCNK9SMN1; SMN2ALDH1A1BRAF
SCHEMBL11045048 0.83 SMARCA2 (0.71) KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL13546240 0.82 KCNQ3 (0.63) KMT2AMEN1SMN1; SMN2LMNAPOLB
SCHEMBL259421 0.81 KCNK3 (0.86) KMT2AMEN1RXFP1KCNK3KCNK9
SCHEMBL259296 0.81 KMT2A (0.80) KMT2AMEN1RXFP1KCNK3KCNK9
SCHEMBL4253897 0.80 KCNK3 (0.93) KMT2AMEN1RXFP1KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
EP-1277738-B1 CONDENSED HETEROARYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2011-03-30 EP disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KMT2A 1722/4885MEN1 3330/4885RXFP1 4866/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KMT2A 1722/4885MEN1 3330/4885RXFP1 4866/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KMT2A 1722/4885MEN1 3330/4885RXFP1 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.